The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE: To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days. MAIN OUTCOMES AND MEASURES: The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events. RESULTS: Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively). CONCLUSIONS AND RELEVANCE: Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01800968.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in earlier smaller studies with liraglutide in patients with HF with reduced left ventricular ejection fraction, the GLP-1RA was associated with increased incidence of serious cardiac events (rhythm disorders, worsening of HF)”
From Safety of Semaglutide (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredIn the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Furthermore, 2 small randomized clinical trials of liraglutide in patients with HF with reduced EF, 1 of which enrolled patients with recent HF hospitalization, suggested potential harm of liraglutide, although neither trial found statistically significant differences.36,37”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [36]
In the citing paper
“In a placebo-controlled FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not associated with an improvement in the composite primary endpoint of death, rehospitalization and NT-proBNP change.181”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Anand, I. S., Fisher, L. D., Chiang, Y., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 857
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Cited by
Sorted by citations
Items 101–200 of 706
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 79
Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review)
Iorga, R., Bacalbașa, N., Carşote, M., Bratu, O. G., Stănescu, A. M. A., BUNGAU, S. G., Pantiș, C., & Diaconu, C. C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8714 · Cited by 79
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 80
Bell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 75
Almutairi, M. G., Gopal, K., Greenwell, A. A., Young, A., Gill, R., Aburasayn, H., Batran, R. A., Chahade, J. J., Gandhi, M., Eaton, F., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.098 · Cited by 74
Levelt, E., Gulsin, G. S., Neubauer, S., & McCann, G. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0724 · Cited by 76
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves, J. S., Borges‐Canha, M., Vasques‐Nóvoa, F., Green, J. B., Leiter, L. A., Granger, C. B., Carvalho, D. M., Leite-Moreira, A. F., Hernandez, A. F., Prato, S. D., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.048 · Cited by 72
Self-citationNagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 70
Ferreira, J. P., Saraiva, F., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D., Packer, M., Zannad, F., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14997 · Cited by 65
GLP-1 receptor agonists and heart failure in diabetes
Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30068-x · Cited by 65
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 63
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Phang, R. J., Ritchie, R. H., Hausenloy, D. J., Lees, J. G., & Lim, S. Y. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac049 · Cited by 67
Packer, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 65
Sharma, A., & Verma, S. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 73
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 65
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 68
Systematic review of incretin therapy during peri-operative and intensive care
Hulst, A. H., Plummer, M. P., Hollmann, M. W., DeVries, J. H., Preckel, B., Deane, A. M., & Hermanides, J. (2018) · Critical Care · doi:10.1186/s13054-018-2197-4 · Cited by 65
Rotkvić, P. G., Planinić, Z., Pršo, A.-M. L., Šikić, J., Galić, E., & Rotkvić, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115973 · Cited by 64
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Gonçalves, E., & Bell, D. S. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0420-6 · Cited by 65
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 65
Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy
Moellmann, J., Klinkhammer, B. M., Onstein, J., Stöhr, R., Jankowski, V., Jankowski, J., Lebherz, C., Tacke, F., Marx, N., Boor, P., et al. (2018) · Diabetes · doi:10.2337/db17-1212 · Cited by 60
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 60
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 80
Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., Leite-Moreira, A. F., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 61
Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 57
Effect of glucose-lowering therapies on heart failure
Nassif, M. E., & Kosiborod, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.211 · Cited by 54
Bonfioli, G. B., Rodella, L., Metra, M., & Vizzardi, E. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10450-6 · Cited by 58
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Giugliano, D., Meier, J. J., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13629 · Cited by 52
Silvetti, S., Belletti, A., Fontana, A., & Pollesello, P. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12177 · Cited by 52
Sharma, A., Mentz, R. J., Granger, B. B., Heitner, J. F., Cooper, L. B., Banerjee, D., Green, C. L., Majumdar, M. D., Eapen, Z. J., Hudson, L. L., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.007 · Cited by 56
Self-citationButler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 54
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 57
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 51
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 56
Cimino, G., Vaduganathan, M., Lombardi, C., Pagnesi, M., Vizzardi, E., Tomasoni, D., Adamo, M., Metra, M., & Inciardi, R. M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14560 · Cited by 62
Pölzl, G., Birgani, S. A., Colet, J. C., Delgado, J. F., Fedele, F., García‐Gonzáles, M. J., Gustafsson, F., Masip, J., Papp, Z., Störk, S., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12366 · Cited by 51
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C. L. B., Li, J., Yang, D.-Y. D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 55
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 52
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 49
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 50
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 50
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 52
Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts
Birkenfeld, A. L., Jordan, J., Dworak, M., Merkel, T., & Burnstock, G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.015 · Cited by 46
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Felker, G. M., Cooper, L. B., Lala, A., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12334 · Cited by 46
Self-citationReducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Management of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 47
Branch, K. R. H., Dagenais, G. R., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Jansky, P., Lakshmanan, M., Lanas, F., Leiter, L. A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2670 · Cited by 41
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
Rossi, V. A., Gruebler, M. R., Monzo, L., Galluzzo, A., & Beltrami, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076838 · Cited by 44
Liu, H., Fu, D., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42
Carbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 44
Paiman, E. H. M., van Eyk, H. J., van Aalst, M., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 42
GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction
Nguyễn, T. D., Shingu, Y., Amorim, P., Schenkl, C., Schwarzer, M., & Doenst, T. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9795-z · Cited by 41
Mentias, A., Desai, M. Y., Aminian, A., Patel, K. V., Keshvani, N., Verma, S., Cho, L., Jacob, M., Alvarez, P., Lincoff, A. M., et al. (2024) · Circulation: Heart Failure · doi:10.1161/circheartfailure.122.010453 · Cited by 40
Witham, M. D., Granic, A., Pearson, E. R., Robinson, S. M., & Sayer, A. A. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01042-4 · Cited by 45
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 40
Rungby, J., Schou, M., Petersen, P. W., Ytte, L., & Andersen, G. S. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000135 · Cited by 39
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 40
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Yang, F., Luo, X., Li, J., Yu, L., Zeng, F., Huang, X., Lan, Y., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113236 · Cited by 43
Adamou, A. T., Barkas, F., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241253988 · Cited by 38
The Current Landscape of Pharmacotherapies for Sarcopenia
Bahat, G., & Özkök, S. (2024) · Drugs & Aging · doi:10.1007/s40266-023-01093-7 · Cited by 41
Consoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 40
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6773-2 · Cited by 39
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 42
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 39
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 35
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34
Treatment of Diabetes in People With Heart Failure
Connelly, K. A., Gilbert, R. E., & Liu, P. X. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.026 · Cited by 35
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure
Greene, S. J., Mentz, R. J., Fiuzat, M., Butler, J., Solomon, S. D., Ambrosy, A. P., Mehta, C. R., Teerlink, J. R., Zannad, F. M., & O’Connor, C. M. (2018) · Circulation · doi:10.1161/circulationaha.118.034668 · Cited by 34
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34
Neves, J. S., Leite, A. R., Mentz, R. J., Holman, R. R., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3478 · Cited by 40
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 40
Sassoon, D., Tune, J. D., Mather, K. J., Noblet, J. N., Eagleson, M. A., Conteh, A. M., Sturek, J. T., & Goodwill, A. G. (2017) · Diabetes · doi:10.2337/db16-1206 · Cited by 35
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 34
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Pölzl, G., Altenberger, J., Baholli, L., Beltrán, P., Borbély, A., Colet, J. C., Delgado, J. F., Fedele, F., Fontana, A., Fruhwald, F. M., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.081 · Cited by 32
Packer, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1185 · Cited by 33
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea
Coats, A. J. S. (2019) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0004 · Cited by 32
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 32
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Stanton, A. M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J. L., & Aroda, V. R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01407-2 · Cited by 33
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.07.004 · Cited by 31
Patel, R. B., & Shah, S. J. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021136 · Cited by 31
Metadata
- Authors
- Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., McNulty, S. E., Anstrom, K. J., Shah, M. R., Braunwald, E., Cappola, T. P., & for the NHLBI Heart Failure Clinical Research Network
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Mayo Clinic (US)
- Brigham and Women's Hospital (US)
- University Hospitals of Cleveland (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Thomas Jefferson University (US)
- Tufts University (US)
- National Heart, Lung, and Blood Institute (US)
- Brigham and Women’s Hospital, Boston, Massachusetts
- Corresponding author
- Margulies, Kenneth B.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-08-02
- Volume
- 316
- Issue
- 5
- Pages
- 500
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5021525
- OpenAlex
- W2505843168
- Cited by
- 706
- References
- 24
- Citations by year
- 2026: 85 · 2025: 99 · 2024: 75 · 2023: 58 · 2022: 46 · 2021: 50 · 2020: 77 · 2019: 68 · 2018: 78 · 2017: 56 · 2016: 13
- FWCI
- 59.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL110297, U10HL110342, U10HL084904, U10HL110262, U01HL084861, U10HL110309, U10HL110336, U10HL110302, U10HL110337, U10HL110312, U10HL110338)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- liraglutide, GLP-1 receptor agonists, advanced heart failure, reduced left ventricular ejection fraction, clinical stability, heart failure readmission, mortality, NT-proBNP, myocardial metabolism, type 2 diabetes, cardiac structure and function, 6-minute walk distance, quality of life, subcutaneous injection, cardioprotection
- MeSH terms
- Liraglutide, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Patient Readmission, Quality of Life, Stroke Volume, United States, Odds Ratio, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
